Smartleaf Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Smartleaf Asset Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.39K	Sell	593 -281	-32%	-$952	﹤0.01%	2986
2026 Q2	$3.22K	Hold	874	–	–	﹤0.01%	2833
2026 Q1	$2.48K	Buy	874 +297	+51%	+$1.15K	﹤0.01%	2902
2025 Q4	$2.37K	Buy	577 +406	+237%	+$2.01K	﹤0.01%	2936
2025 Q3	$839	Buy	+171	New	+$898	﹤0.01%	2778
2025 Q1	–	Sell	-269	Closed	-$1.82K	–	2979
2024 Q4	$1.82K	Hold	269	–	–	﹤0.01%	2553
2024 Q3	$1.88K	Buy	269 +249	+1,245%	+$1.78K	﹤0.01%	2492
2024 Q2	$151	Buy	+20	New	+$174	﹤0.01%	2703

Other funds holding RXRX

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 38.25% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $296B AUM 23.14% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Smartleaf Asset Management's RXRX Position: Q3 2026 in Review

Smartleaf Asset Management reduced its Recursion Pharmaceuticals (RXRX) stake by 32% in Q3 2026, selling an estimated $952 and leaving 593 shares worth $2.39K. The position accounts for ﹤0.01% of the portfolio, ranked #2986.

Smartleaf Asset Management first reported a position in RXRX in Q2 2024 and has held it in 8 quarters since. The position peaked at $3.22K in Q2 2026. 207 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.

Smartleaf Asset Management held 593 shares of Recursion Pharmaceuticals worth $2.39K as of Q3 2026.
Smartleaf Asset Management sold 281 Recursion Pharmaceuticals shares in Q3 2026, an estimated $952.
Recursion Pharmaceuticals made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q3 2026, its #2986 holding.
Smartleaf Asset Management first reported a position in Recursion Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
Smartleaf Asset Management's Recursion Pharmaceuticals position peaked at $3.22K in Q2 2026.
207 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.

Based on Smartleaf Asset Management's 13F filing for Q3 2026, filed 10 Nov 2026.